Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.
Type:
Grant
Filed:
June 12, 2014
Date of Patent:
May 21, 2019
Assignee:
Pharis Biotec GmbH
Inventors:
Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
Abstract: An N-terminally protected peptide having the sequence (SEQ ID NO: 1) X-Glu-Cys-Lys-Ile-Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln, wherein X is a group protecting the N-terminal of the peptide.
Type:
Grant
Filed:
April 30, 2014
Date of Patent:
November 13, 2018
Assignee:
Pharis Biotec GmbH
Inventors:
Wolf-Georg Forssmann, Andreas Zgraja, Rudolf Richter
Abstract: An N-terminally protected peptide having the sequence (SEQ ID NO: 1) X-Glu-Cys-Lys-Ile-Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln, wherein X is a group protecting the N-terminal of the peptide.
Abstract: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary electrophoresis, as well as to appropriate processes for the preparation of same.
Type:
Application
Filed:
July 27, 2007
Publication date:
September 24, 2009
Applicant:
Pharis Biotec GmbH
Inventors:
Hansueli Immer, Wolf-Georg Forssmann, Knut Adermann, Christian Klessen
Abstract: A serine protease inhibitor, characterized by having a domain with four cysteines, and a sequence of 0 to 20 amino acids is present between the first and second cysteines, or the serine protease inhibitor has a domain with six cysteines, and a sequence of 7 to 20 amino acids is present between the first and second cysteines.
Type:
Grant
Filed:
December 23, 1998
Date of Patent:
May 16, 2006
Assignee:
Pharis Biotec GmbH
Inventors:
Wolf-Georg Forssmann, Hans-Jürgen Magert, Ludger Ständker, Peter Kreuztmann
Abstract: The present invention relates to antibiotically active natriuretic peptides for use as antibiotically active preparations prepared using biotechnological and recombinant methods and chemical synthesis. The antibiotically active peptides are referred to as natriubiotics. After chemical peptide synthesis, these natriubiotics can be used as human or veterinary medicaments in a suitable galenic formulation or as food additives.
Type:
Grant
Filed:
November 17, 2004
Date of Patent:
April 25, 2006
Assignee:
Pharis Biotec GmbH
Inventors:
Wolf-Georg Forssmann, Alexander Krause, Erik Maronde
Abstract: Pepetides having bifidogenic properties are obtainable by the process of adding proteases to cow'milk or human milk, followed by incubation, centrifugation, acidification, purification by reverse phase HPLC and cation-exchange HPLC, culturing Bifidobacterium bifidum and E. coli in the presence of collected bifidogenic fractions, and isolation of the peptides having bifidogenic properties, and the isolated peptides can be amidated, acetylated, sulfated, phosphorylated, glycosylated, oxidized, or fragmented and still maintain their bifidogenic properties, and combination peptides having bifidogenic properties are obtainable by chemically bonding the peptides having bifidogenic properties, the amidated, acetylated, sulfated, phosphorylated, glycosylated, oxidized, or fragmented peptides having bifidogenic properties, or combinations thereof.
Abstract: The present invention relates to a quick method for the qualitative and quantitative medical-diagnostic analysis on the protein level of the substitution of single amino acids with pathogenic and non-pathogenic effects on the organism. The medical-diagnostic analysis is performed by a combination of enzymatic or chemical cleavage of the isolated peptide, chromatographical separation of the fragments and analysis by mass spectrometry, both direct LC/MS and indirect MALDI-MS, and analysis by capillary electrophoresis. By comparing protein samples from healthy humans with those of ill humans, the method described is suitable for establishing new, as yet unknown mutations and quantifying the expression and incorporation of wild type to mutant.
Type:
Grant
Filed:
April 6, 1999
Date of Patent:
December 4, 2001
Assignee:
Pharis Biotec GmbH
Inventors:
Wolf-Georg Forssmann, Manfred Raida, Bernhard Brenner, Volker Nier